These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15197712)

  • 1. Diagnosis and management of pergolide-induced fibrosis.
    Agarwal P; Fahn S; Frucht SJ
    Mov Disord; 2004 Jun; 19(6):699-704. PubMed ID: 15197712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retroperitoneal fibrosis caused by pergolide in a patient with Parkinson's disease.
    Bilici A; Karadag B; Doventas A; Erdincler DS; Cetinkaya S; Ogut G; Tezcan V; Beger T
    Neth J Med; 2004 Nov; 62(10):389-92. PubMed ID: 15683095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pergolide-induced retroperitoneal fibrosis.
    Mondal BK; Suri S
    Int J Clin Pract; 2000; 54(6):403. PubMed ID: 11092116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rounded atelectasis and respiratory compromise secondary to pergolide use.
    Bloom CI; Wilson GE
    Respirology; 2009 Aug; 14(6):906-7. PubMed ID: 19659834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
    Jiménez-Jiménez FJ; López-Alvarez J; Sánchez-Chapado M; Montero E; Miquel J; Sierra A; Gutiérrez F
    Clin Neuropharmacol; 1995 Jun; 18(3):277-9. PubMed ID: 8635187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pericardial, retroperitoneal, and pleural fibrosis induced by pergolide.
    Shaunak S; Wilkins A; Pilling JB; Dick DJ
    J Neurol Neurosurg Psychiatry; 1999 Jan; 66(1):79-81. PubMed ID: 9886458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Parkinson's disease with ropinirole after pergolide-induced retroperitoneal fibrosis.
    Lund BC; Neiman RF; Perry PJ
    Pharmacotherapy; 1999 Dec; 19(12):1437-8. PubMed ID: 10600093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pergolide-induced pleuropulmonary fibrosis.
    Bleumink GS; van der Molen-Eijgenraam M; Strijbos JH; Sanwikarja S; van Puijenbroek EP; Stricker BH
    Clin Neuropharmacol; 2002; 25(5):290-3. PubMed ID: 12410064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ergoline-induced retroperitoneal fibrosis].
    Munksgaard L; Madsen H; Svolgaard PB; Rasmussen JM
    Ugeskr Laeger; 2006 Feb; 168(9):921-2. PubMed ID: 16513059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ergoline-induced retroperitoneal fibrosis].
    Christoffersen CL; Siboni AH; Boisen E; Ladefoged C; Rasmussen C; Christensen-Dalsgaard S; Jakobsen P; Rasmussen LD; Schlander S
    Ugeskr Laeger; 2006 Apr; 168(17):1667; author reply 1667. PubMed ID: 16674890
    [No Abstract]   [Full Text] [Related]  

  • 11. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
    Sánchez-Chapado M; Angulo Cuesta J; Guil Cid M; Jiménez FJ; López Alvarez YJ
    Arch Esp Urol; 1995 Dec; 48(10):979-83. PubMed ID: 8588730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
    Tintner R; Manian P; Gauthier P; Jankovic J
    Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
    Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
    Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Refractory generalized edema: an infrequent complication of long-term pergolide treatment for Parkinson disease.
    Bianchi M; Castiglioni MG
    Clin Neuropharmacol; 2005; 28(5):245-6. PubMed ID: 16239767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pergolide use and heart valve fibrosis. Yearly control in patients with Parkinson disease who use pergolide].
    van Laar T; Berendse H; Bloem BR; Boon AJ; van Hilten JJ; Hovestadt A; de Koning-Tijssen MA; Nijssen PC; Weber WE
    Ned Tijdschr Geneeskd; 2009 Jan; 153(3):87-90. PubMed ID: 19235345
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retroperitoneal fibrosis caused by treatment with pergolide in a patient with Parkinson's disease.
    Kunkler RB; Osborn DE; Abbott RJ
    Br J Urol; 1998 Jul; 82(1):147. PubMed ID: 9698685
    [No Abstract]   [Full Text] [Related]  

  • 20. [Sleep attacks and pergolide mesylate].
    García Ruiz PJ; Hernández J; Cantarero S; Fanjul S
    Neurologia; 2001 Feb; 16(2):92. PubMed ID: 11257938
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.